靶向骨髓造血微环境治疗急性髓系白血病的研究进展  

Progress of targeted bone marrow hematopoietic microenvironment for acute myeloid leukemia

作　　者：赵进莲 满艳 杨同华[2] 王娅婕 Zhao Jinlian;Man Yan;Yang Tonghua;Wang Yajie(Medical College of Kunming University of Science and Technology,Kunming 650500,China;Department of Hematology,the First People′s Hospital of Yunnan Province,Kunming 650032,China)

机构地区：[1]昆明理工大学医学院,昆明650500 [2]云南省第一人民医院血液科,昆明650032

出　　处：《白血病．淋巴瘤》2022年第12期762-765,共4页Journal of Leukemia & Lymphoma

基　　金：国家自然科学基金(82070173);云南省地方基础研究专项优秀青年项目(202101AW070017)。

摘　　要：急性髓系白血病(AML)是造血系统的髓系原始细胞克隆性恶性增殖性疾病。尽管进行积极的联合化疗和造血干细胞移植能改善AML患者的生存,但预后仍不理想。以往研究表明骨髓造血微环境(BMM)对白血病干细胞的异常调节是AML难以完全治愈及复发的重要因素之一。关于AML分子生物学及BMM的研究日益增多,深入探讨急性白血病微环境的改变,靶向干预异常的BMM有望在AML的靶向治疗及改善患者预后方面取得进展。Acute myeloid leukemia(AML)is a malignant clonal proliferative disease of immature myeloid cells in hematopoietic system.Although chemotherapy and hematopoietic stem cell transplantation could improve the survival of AML patients,their prognoses are still poor.Previous studies have shown that the abnormal regulation of bone marrow microenvironment(BMM)on leukemia stem cells is one of the important factors that make AML difficult to completely cure and easy to relapse.Studies on AML molecular biology and BMM are increasing.In-depth investigation on the changes of acute leukemia microenvironment and targeted intervention of abnormal BMM are expected to make new breakthroughs in the targeted therapy of AML and to improve the prognosis of patients.This review reviews the progress of BMM and targeted microenvironment therapy in AML.

关 键 词：白血病 髓样 急性 肿瘤微环境 间充质干细胞 外泌体 代谢 

分 类 号：R733.71[医药卫生—肿瘤]